RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Corey A., Oronsky, Bryan T., Caroen, Scott Z., Scicinski, Jan J., Degesys, Aiste, Kim, Michelle M., Oronsky, Arnold L., Lybeck, Harry, Cabrales, Pedro, Oronsky, Neil, Reid, Tony, Roswarski, Joseph, Brzezniak, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Published online: March, 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821137/
https://www.ncbi.nlm.nih.gov/pubmed/27065849
http://dx.doi.org/10.1159/000444631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821137/
https://www.ncbi.nlm.nih.gov/pubmed/27065849
http://dx.doi.org/10.1159/000444631

Ejemplares similares